Claims
- 1. A syn compound of the formula: ##STR37## wherein R.sup.2 is an aliphatic hydrocarbon residue substituted with halogen, carboxy or esterified carboxy, or cycloalkyl;
- R.sup.5 is carboxy or functionally modified carboxy and R.sup.6 is amino or protected amino, and pharmaceutically acceptable salt thereof.
- 2. A syn compound of the formula: ##STR38## wherein R.sup.2 is alkyl substituted with halogen, carboxy or esterified carboxy; or cyclo (lower) alkyl;
- R.sup.5 is carboxy or functionally modified carboxy and
- R.sup.6 is amino or protected amino, and pharmaceutically acceptable salt thereof.
- 3. A syn compound of the formula: ##STR39## wherein R.sup.2 is cycloalkyl,
- R.sup.5 is carboxy or esterified carboxy and
- R.sup.6 is amino or protected amino, and pharmaceutically acceptable salt thereof.
- 4. A syn compound of the formula: ##STR40## wherein R.sup.2 is alkyl substituted with halogen, carboxy or lower alkoxycarbonyl,
- R.sup.5 is carboxy or esterified carboxy and
- R.sup.6 is amino or protected amino, and pharmaceutically acceptable salt thereof.
- 5. The compound of the claim 3, wherein R.sup.6 is amino or lower alkanamido.
- 6. The compound of the claim 5, wherein R.sup.6 is amino or formamido and R.sup.5 is carboxy.
- 7. The compound of claim 6, which is 7-[2-(2-aminothiazol-4-yl)-2-cyclohexyloxyiminoacetamido]-3-cephem-4-carboxylic acid (syn isomer).
- 8. The compound of the claim 6, which is 7-[2-(2-formamidothiazol-4-yl)-2-cyclohexyloxyiminoacetamido]-3-cephem-4-carboxylic acid (syn isomer).
- 9. The compounds of the claim 5, wherein R.sup.6 is amino or formamido and R.sup.5 is substituted benzyloxycarbonyl.
- 10. The compound of the claim 9, which is p-nitrobenzyl 7-[2-(2-formamidothiazol-4-yl)-2-cyclohexyloxyiminoacetamido]-3-cephem-4-carboxylate (syn isomer).
- 11. The compound of the claim 4, wherein R.sup.2 is haloalkyl, and R.sup.6 is amino or lower alkanamido.
- 12. The compound of the claim 11, wherein R.sup.2 is monohalo(lower)alkyl or trihalo(lower)alkyl, and R.sup.5 is carboxy.
- 13. The compound of the claim 12, which is 7-[2-(2-aminothiazol-4-yl)-2-(2-chloroethoxy)iminoacetamido]-3-cephem-4-carboxylic acid (syn isomer).
- 14. The compound of the claim 12, which is 7-[2-(2-formamidothiazol-4-yl)-2-(2-chloroethoxy)iminoacetamido]-3-cephem-4-carboxylic acid (syn isomer).
- 15. The compound of the claim 12, which is 7-[2-(2-aminothiazol-4-yl)-2-(2,2,2-trifluoroethoxy)iminoacetamido]-3-cephem-4-carboxylic acid (syn isomer).
- 16. The compound of the claim 12, which is 7-[2-(2-formamidothiazol-4-yl)-2-(2,2,2-trifluoroethoxy)iminoacetamido]-3-cephem-4-carboxylic acid (syn isomer).
- 17. The compound of the claim 1, wherein R.sup.2 is carboxy(lower)alkyl and R.sup.6 is amino or lower alkanamido.
- 18. The compound of the claim 17, which is 7-[2-(2-aminothiazol-4-yl)-2-carboxymethoxyiminoacetamido]-3-cephem-4-carboxylic acid (syn isomer).
- 19. The compound of the claim 17, which is 7-[2-(2-formamidothiazol-4-yl)-2-carboxymethoxyiminoacetamido]-3-cephem-4-carboxylic acid (syn isomer).
- 20. The compound of the claim 19, wherein R.sup.2 is lower alkoxycarbonyl(lower)alkyl and R.sup.6 is amino or lower alkanamido.
- 21. The compound of the claim 20, wherein R.sup.5 is carboxy.
- 22. The compound of the claim 21, which is 7-[2-(2-aminothiazol-4-yl)-2-ethoxycarbonylmethoxyiminoacetamido]-3-cephem-4-carboxylic acid (syn isomer).
- 23. The compound of the claim 20, which is 7-[2-(2-formamidothiazol-4-yl)-2-ethoxycarbonylmethoxyiminoacetamido]-3-cephem-4-carboxylic acid (syn isomer).
- 24. The compound of the claim 20, which is 7-[2-(2-formamidothiazol-4-yl)-2-tertbutoxycarbonylmethoxyiminoacetamido]-3-cephem-4-carboxylic acid (syn isomer).
- 25. The compound of the claim 20, wherein R.sup.5 is substituted benzyloxycarbonyl.
- 26. The compound of the claim 25, which is p-nitrobenzyl 7-[2-(2-formamidothiazol-4-yl)-2-ethoxycarbonylmethoxyiminoacetamido]-3-cephem-4-carboxylate (syn isomer).
- 27. An antibacterial composition comprising, as an effective ingredient, the compound of claim 1, in association with a pharmaceutically acceptable, substantially nontoxic carrier or excipient.
- 28. A method for treating an infectious disease caused by pathogens, which comprises administering the compound of claim 1 to infected human being or animals.
Priority Claims (4)
Number |
Date |
Country |
Kind |
10699/77 |
Mar 1977 |
GBX |
|
29245/77 |
Jul 1977 |
GBX |
|
42315/77 |
Oct 1977 |
GBX |
|
75/78 |
Jan 1978 |
GBX |
|
Parent Case Info
This is a division of application Ser. No. 886,340, filed Mar. 14, 1978 and of application Ser. No. 302,668 filed Sept. 15, 1981 now U.S. Pat. No. 4,427,674.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4254119 |
Hamashima et al. |
Mar 1981 |
|
4278793 |
Durchleims et al. |
Jul 1981 |
|
4396618 |
Heyma et al. |
Aug 1983 |
|
Related Publications (1)
|
Number |
Date |
Country |
|
302668 |
Sep 1981 |
|
Divisions (1)
|
Number |
Date |
Country |
Parent |
886340 |
Mar 1978 |
|